ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol.24(14), 2137–2150 (2006).
   PubMed Web of Science ®Google Scholar
• Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin. Oncol.31(4), 450–464 (2004).
   PubMed Web of Science ®Google Scholar
• Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer72(1), 37–41 (1993).
   PubMed Web of Science ®Google Scholar
• Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol.8(2), 163–168 (1997).
   PubMed Web of Science ®Google Scholar
• Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer71(3), 587–591 (1995).
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shimada Y, Yoshida S et al. Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). Eur. J. Cancer30A(14), 2091–2093 (1994).
   PubMed Web of Science ®Google Scholar
• Lacave AJ, Baron FJ, Anton LM et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a Phase II trial. Ann. Oncol.2(10), 751–754 (1991).
   PubMed Web of Science ®Google Scholar
• Rougier P, Ducreux M, Mahjoubi M et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A Phase II trial with prognostic factor analysis. Eur. J. Cancer30A(9), 1263–1269 (1994).
   PubMedGoogle Scholar
• Kim NK, Park YS, Heo DS et al. A Phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer71(12), 3813–3818 (1993).
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shimada Y, Shirao K et al. Randomized Phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J. Clin. Oncol.21(1), 54–59 (2003).
   PubMed Web of Science ®Google Scholar
• Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized Phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol.18(14), 2648–2657 (2000).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med.355(1), 11–20 (2006).
   PubMed Web of Science ®Google Scholar
• Kang YK, Kang WK, Shin DB et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised Phase III noninferiority trial. Ann. Oncol.20(4), 666–673 (2009).
   PubMed Web of Science ®Google Scholar
• Hendlisz A, Bleiberg H. Diagnosis and treatment of gastric cancer. Drugs49(5), 711–720 (1995).
   Google Scholar
• Schipper DL, Wagener DJ. Chemotherapy of gastric cancer. Anticancer Drugs7(2), 137–149 (1996).
   PubMed Web of Science ®Google Scholar
• Hansen RM. 5-Fluorouracil by protracted venous infusion: a review of recent clinical studies. Cancer Invest.9(6), 637–642 (1991).
   PubMed Web of Science ®Google Scholar
• Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol.24(18), 2903–2909 (2006).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol.24(31), 4991–4997 (2006).
   PubMed Web of Science ®Google Scholar
• Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Combination chemotherapies in advanced gastric cancer: an updated systemic review and meta-analysis. Proc. Am. Soc. Clin. Oncol.25, 18S (2007) (Abstract 4555).
   Google Scholar
• Ajani JA. Standard of care for gastric cancer based on meta-analysis? Treading on thin ice or it is very nice! J. Clin. Oncol.24(34), 5473–5474; author reply 5474–5476 (2006).
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Jager E, Scholz M. Chemotherapy for advanced gastric cancer. J. Clin. Oncol.25(6), 729; author reply 730 (2007).
   Google Scholar
• Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest. New Drugs18(4), 343–354 (2000).
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res.58(4), 685–690 (1998).
   PubMed Web of Science ®Google Scholar
• Verweij J. Rational design of new tumoractivated cytotoxic agents. Oncology57(Suppl. 1), 9–15 (1999).
   Google Scholar
• Koizumi W, Saigenji K, Ujiie S, Terashima M, Sakata Y, Taguchi T. A pilot Phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology64(3), 232–236 (2003).
   PubMed Web of Science ®Google Scholar
• Sakamoto J, Chin K, Kondo K et al. Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs17(2), 231–236 (2006).
   PubMed Web of Science ®Google Scholar
• Leon-Rodriguez E, Green D, Candelaria M. Oral capecitabine in the treatment of patients with advanced or metastatic gastric carcinoma [abstract]. Ann. Oncol.191(13 Suppl.), 708P (2003).
   Google Scholar
• Kim TW, Kang YK, Ahn JH et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann. Oncol.13(12), 1893–1898 (2002).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med.358(1), 36–46 (2008).
   PubMed Web of Science ®Google Scholar
• Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann. Oncol.20(9), 1529–1534 (2009).
   PubMed Web of Science ®Google Scholar
• Chang C, Chao Y, Chen J et al. Pharmacoeconomic analysis of capecitabine for advanced gastric cancer in Taiwan. J. Clin. Oncol.26, (2008) (Abstract 15576).
   Google Scholar
• Boku N. Chemotherapy for metastatic disease: review from JCOG trials. Int. J. Clin. Oncol.13(3), 196–200 (2008).
   PubMedGoogle Scholar
• Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a Phase III trial. Lancet Oncol.9(3), 215–221 (2008).
   PubMed Web of Science ®Google Scholar
• Ajani JA, Rodriquez W, Bodoky G et al. Multicenter Phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS). Gastrointestinal Cancers Symposium (2009) (Abstract 8).
   Google Scholar
• Lee JL, Kang YK, Kang HJ et al. A randomised multicentre Phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br. J. Cancer99(4), 584–590 (2008).
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Lee FC, Haller DG et al. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter Phase II study. Cancer109(1), 33–40 (2007).
   PubMed Web of Science ®Google Scholar
• Lee JL, Kang HJ, Kang YK et al. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer. Cancer Chemother. Pharmacol.61(5), 837–845 (2008).
   PubMedGoogle Scholar
• Haller DG, Cassidy J, Clarke SJ et al. Potential regional differences for the tolerability profiles of fluoropyrimdines. J. Clin. Oncol.26(13), 2118–2123 (2008).
   PubMed Web of Science ®Google Scholar
• Shirao K, Hoff PM, Ohtsu A, et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: a joint United States and Japan Study of UFT/LV. J. Clin. Oncol.22(17), 3466–3474 (2004).
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hartmann JT, Probst S et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol.26(9), 1435–1442 (2008).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor recepter 2 (HER2)-positive advanced gastric cancer (GC). J. Clin. Oncol.27(18s), (2009) (Abstract LBA4509).
   Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med.357(18), 1810–1820 (2007).
   PubMed Web of Science ®Google Scholar